search
Back to results

Wireless Nerve Stimulation Device To Enhance Recovery After Stroke

Primary Purpose

Stroke, Chronic Stroke, Upper Extremity Paresis

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Active Vagus Nerve Stimulation
Placebo Vagus Nerve Stimulation
Sponsored by
Baylor Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional device feasibility trial for Stroke focused on measuring Vagus Nerve Stimulation (VNS), Rehabilitation, Targeted Plasticity Therapy

Eligibility Criteria

22 Years - 79 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Adult, aged 22-79
  • Ischemic stroke that occurred ≥ 12 months prior to enrollment
  • UEFM score of 20 to 50
  • Modified Rankin Score of 2, 3, or 4
  • Right vocal cord has normal movement when assessed by laryngoscopy
  • Women of reproductive potential must use contraceptive protection
  • Meets all clinical criteria for the surgical VNS implantation as determined by the PI, surgeon, and anesthesiologist

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Deficits in language or attention that interfere with study participation
  • Severe spasticity (Modified Ashworth ≥ 3)
  • Medical or mental instability that would likely interfere with study protocol
  • Receiving any therapy (medication or otherwise) that would interfere with VNS, such as drugs that perturb neurotransmitter action (anticholinergics, adrenergic blockers, etc.)
  • Presence of any other implanted electrical stimulation device
  • Prior injury to vagus nerve
  • Lactating, pregnant, or plan to become pregnant
  • Participation in another interventional clinical trial
  • Clinical complications that hinder or contraindicate the surgical procedure
  • Abusive use of alcohol and/or illegal substances use
  • Active neoplastic disease.
  • Any medical condition or other circumstances that might interfere with their ability to return for follow-up visits in the judgment of the Investigator.
  • Any condition which, in the judgment of the Investigator, would preclude adequate evaluation of device's safety and performance.
  • Recent history of syncope
  • Recent history of dysphagia
  • Current or anticipated requirement for diathermy

Sites / Locations

  • Baylor Scott & White Institute for RehabilitationRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Immediate Start Vagus Nerve Stimulation group

Delayed Start Vagus Nerve Stimulation group

Arm Description

The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.

The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.

Outcomes

Primary Outcome Measures

Incidence of Adverse Events [Device Safety]
Review of adverse events reported throughout the trial will be used to inform the potential risks associated with the ReStore system and provide a better understanding of risk/benefit analysis

Secondary Outcome Measures

ReStore Stimulation Successes
The percentage of stimulation attempts classified as 'Success' from the total number of stimulation attempts made will be calculated for each participant and the mean percent of successful attempts across all participants will be used as the outcome measure.
Upper-Extremity Fugl-Meyer Assessment (UEFM)
The UEFM Assessment is a sixty-six point assessment of mobility administered by a therapist designed to facilitate consistent collection and reporting of basic upper extremity findings. The endpoint will be: estimate the shift in UEFM assessment following active VNS
Wolf Motor Task Functional Ability Scale
The Wolf Motor Task Functional Ability Scale (WMFT-FAS) is a quantitative measure of upper extremity motor ability through timed and functional tasks. The task includes evaluation of dexterity, strength, and upper extremity function. Functional ability is measured on a 6-point ordinal scale (0-5) with a maximum total score of 75. The endpoint will be: estimate the shift in WMFT-FAS assessment following active VNS
Action Research Arm Test
The ARAT is a nineteen-item observational assessment of upper limb function. The areas of assessment include activities of daily living, coordination, dexterity, and upper extremity function. The endpoint will be: Estimate the shift in ARAT assessment following active VNS
Modified Rankin Scale
The Modified Rankin Scale (MRS) is a single item global outcomes rating scale that categorizes level of functional independence. The measure reflects ability to perform activities of daily living and functional mobility. The MRS is a 6 point scale with 0 being no disability and 5 being severe disability. A score of 6 indicates that the patient has expired. The endpoint will be: Estimate the shift in MRS assessment following active VNS
Quantitative Force and Range of Motion Assessment
The Quantitative Force and Range of Motion Assessment form is a physical assessment of upper limb changes in force/torque as a result of VNS paired rehabilitation. The endpoints will be: 10% increase in finger pinch and flexion force following active VNS; 10% increase in wrist flexion and extension force following active VNS; 10% increase in wrist pronation and supination force following active VNS

Full Information

First Posted
August 18, 2020
Last Updated
September 12, 2023
Sponsor
Baylor Research Institute
Collaborators
The University of Texas at Dallas, University of Texas Southwestern Medical Center, National Institute of Neurological Disorders and Stroke (NINDS)
search

1. Study Identification

Unique Protocol Identification Number
NCT04534556
Brief Title
Wireless Nerve Stimulation Device To Enhance Recovery After Stroke
Official Title
Wireless Nerve Stimulation Device To Enhance Recovery After Stroke
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2021 (Actual)
Primary Completion Date
January 31, 2024 (Anticipated)
Study Completion Date
January 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baylor Research Institute
Collaborators
The University of Texas at Dallas, University of Texas Southwestern Medical Center, National Institute of Neurological Disorders and Stroke (NINDS)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Texas Biomedical Device Center (TxBDC) has developed an innovative strategy to enhance recovery of motor and sensory function after neurological injury termed targeted plasticity therapy (TPT). This technique uses brief pulses of vagus nerve stimulation to engage pro-plasticity neuromodulatory circuits during rehabilitation exercises. Preclinical findings demonstrate that VNS paired with rehabilitative training enhances recovery in multiple models of neurological injury, including stroke, spinal cord injury, intracerebral hemorrhage, and traumatic brain injury. Recovery is associated with neural plasticity in spared motor networks in the brain and spinal cord. Moreover, two initial studies and a recently completed Phase 3 clinical trial using a commercially available device demonstrates that paired VNS with rehabilitation is safe and improves motor recovery after stroke. The purpose of this study is to extend these findings and evaluate whether VNS delivered with the new device paired with rehabilitation represents a safe and feasible strategy to improve recovery of motor and sensory function in participants with stroke.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Chronic Stroke, Upper Extremity Paresis, Ischemic Stroke, Hemorrhagic Stroke
Keywords
Vagus Nerve Stimulation (VNS), Rehabilitation, Targeted Plasticity Therapy

7. Study Design

Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Prospective, double blind, randomized placebo controlled, plus open-label extension
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Immediate Start Vagus Nerve Stimulation group
Arm Type
Experimental
Arm Description
The Immediate Start VNS group will receive rehabilitation and active stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
Arm Title
Delayed Start Vagus Nerve Stimulation group
Arm Type
Placebo Comparator
Arm Description
The Delayed Start VNS group will receive equivalent rehabilitation with placebo stimulation for 18 in-office sessions over the course of approximately six weeks during Phase 1. For Phase 2, all subjects will be provided with the option to participate in an open-label extension consisting of an additional 18 sessions of in-office rehabilitation with active VNS over the course of approximately six weeks. Additionally, participants may be provided with a system of rehabilitative devices to utilize at home.
Intervention Type
Device
Intervention Name(s)
Active Vagus Nerve Stimulation
Other Intervention Name(s)
VNS, vagus nerve stimulation, paired VNS
Intervention Description
Stimulation of the vagus nerve that is paired with upper limb rehabilitation. VNS stimulation as described in the current study consists of 0.5 second trains of 0.8 mA; 100 µsec biphasic pulses at 30 Hz. Stimulation trains are delivered only during rehabilitation.
Intervention Type
Device
Intervention Name(s)
Placebo Vagus Nerve Stimulation
Other Intervention Name(s)
placebo, control
Intervention Description
During Phase 1 of the study, the placebo group will receive a minimal amount of stimulation that fails to sufficiently activate the nerve, unknown to the participant and therapists. All participants will receive active stimulation during the Phase 2 open-label portion of the study.
Primary Outcome Measure Information:
Title
Incidence of Adverse Events [Device Safety]
Description
Review of adverse events reported throughout the trial will be used to inform the potential risks associated with the ReStore system and provide a better understanding of risk/benefit analysis
Time Frame
From Week 1 through study follow-up, approximately two years after the final session of rehabilitation
Secondary Outcome Measure Information:
Title
ReStore Stimulation Successes
Description
The percentage of stimulation attempts classified as 'Success' from the total number of stimulation attempts made will be calculated for each participant and the mean percent of successful attempts across all participants will be used as the outcome measure.
Time Frame
Weeks 6-11
Title
Upper-Extremity Fugl-Meyer Assessment (UEFM)
Description
The UEFM Assessment is a sixty-six point assessment of mobility administered by a therapist designed to facilitate consistent collection and reporting of basic upper extremity findings. The endpoint will be: estimate the shift in UEFM assessment following active VNS
Time Frame
Weeks 1, 5, 12, 19, 20, 24, 32
Title
Wolf Motor Task Functional Ability Scale
Description
The Wolf Motor Task Functional Ability Scale (WMFT-FAS) is a quantitative measure of upper extremity motor ability through timed and functional tasks. The task includes evaluation of dexterity, strength, and upper extremity function. Functional ability is measured on a 6-point ordinal scale (0-5) with a maximum total score of 75. The endpoint will be: estimate the shift in WMFT-FAS assessment following active VNS
Time Frame
Weeks 1, 5, 12, 19, 20, 24, 32
Title
Action Research Arm Test
Description
The ARAT is a nineteen-item observational assessment of upper limb function. The areas of assessment include activities of daily living, coordination, dexterity, and upper extremity function. The endpoint will be: Estimate the shift in ARAT assessment following active VNS
Time Frame
Weeks 1, 5, 12, 19, 20, 24, 32
Title
Modified Rankin Scale
Description
The Modified Rankin Scale (MRS) is a single item global outcomes rating scale that categorizes level of functional independence. The measure reflects ability to perform activities of daily living and functional mobility. The MRS is a 6 point scale with 0 being no disability and 5 being severe disability. A score of 6 indicates that the patient has expired. The endpoint will be: Estimate the shift in MRS assessment following active VNS
Time Frame
Weeks 1, 5, 12, 19, 20, 24, 32
Title
Quantitative Force and Range of Motion Assessment
Description
The Quantitative Force and Range of Motion Assessment form is a physical assessment of upper limb changes in force/torque as a result of VNS paired rehabilitation. The endpoints will be: 10% increase in finger pinch and flexion force following active VNS; 10% increase in wrist flexion and extension force following active VNS; 10% increase in wrist pronation and supination force following active VNS
Time Frame
Weeks 1, 5-20, 24, 32

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and availability for the duration of the study Adult, aged 22-79 Ischemic or hemorrhagic stroke that occurred ≥ 12 months prior to enrollment UEFM score of 20 to 50 Modified Rankin Score of 2, 3, or 4 Right vocal cord has normal movement when assessed by laryngoscopy Women of reproductive potential must use contraceptive protection Meets all clinical criteria for the surgical VNS implantation as determined by the PI, surgeon, and anesthesiologist Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this study: Deficits in language or attention that interfere with study participation Severe spasticity (Modified Ashworth ≥ 3) Medical or mental instability that would likely interfere with study protocol Receiving any therapy (medication or otherwise) that would interfere with VNS, such as drugs that perturb neurotransmitter action (anticholinergics, adrenergic blockers, etc.) Presence of any other implanted electrical stimulation device Prior injury to vagus nerve Lactating, pregnant, or plan to become pregnant Participation in another interventional clinical trial Clinical complications that hinder or contraindicate the surgical procedure Abusive use of alcohol and/or illegal substances use Participants with sickle cell, lupus, clotting disorders or active neoplastic disease. Participants with any any medical condition or other circumstances that might interfere with their ability to return for follow-up visits in the judgment of the Investigator. Any condition which, in the judgment of the Investigator, would preclude adequate evaluation of device's safety and performance. Recent history of syncope Recent history of dysphagia Current or anticipated requirement for diathermy Uncontrolled hypertension Diagnosed with Cerebral amyloid angiopathy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alvaro Carrera
Phone
469-831-5321
Email
alvaro.carrera@bswhealth.org
First Name & Middle Initial & Last Name or Official Title & Degree
Aimee Muir
Phone
214-820-9356
Email
aimee.muir@bswhealth.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Kilgard, PhD
Organizational Affiliation
University of Texas at Dallas
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert Rennaker, PhD
Organizational Affiliation
University of Texas at Dallas
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Seth Hays, PhD
Organizational Affiliation
University of Texas at Dallas
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jane Wigginton, MD
Organizational Affiliation
University of Texas Southwestern Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rita Hamilton, DO
Organizational Affiliation
Baylor Scott & White Institute for Rehabilitation
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michael Foreman, MD, FACS
Organizational Affiliation
Baylor Health Care System
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Richard Naftalis, MD, FAANS, FACS
Organizational Affiliation
Baylor Health Care System
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Mark Powers, PhD
Organizational Affiliation
Baylor Health Care System
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ann Marie Warren, PhD
Organizational Affiliation
Baylor Health Care System
Official's Role
Study Director
Facility Information:
Facility Name
Baylor Scott & White Institute for Rehabilitation
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alvaro Carerra
Phone
469-831-5321
Email
alvaro.carerra@bswhealth.org

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30983963
Citation
Engineer ND, Kimberley TJ, Prudente CN, Dawson J, Tarver WB, Hays SA. Targeted Vagus Nerve Stimulation for Rehabilitation After Stroke. Front Neurosci. 2019 Mar 29;13:280. doi: 10.3389/fnins.2019.00280. eCollection 2019.
Results Reference
background
PubMed Identifier
23954448
Citation
Khodaparast N, Hays SA, Sloan AM, Hulsey DR, Ruiz A, Pantoja M, Rennaker RL 2nd, Kilgard MP. Vagus nerve stimulation during rehabilitative training improves forelimb strength following ischemic stroke. Neurobiol Dis. 2013 Dec;60:80-8. doi: 10.1016/j.nbd.2013.08.002. Epub 2013 Aug 15.
Results Reference
background
PubMed Identifier
24553102
Citation
Khodaparast N, Hays SA, Sloan AM, Fayyaz T, Hulsey DR, Rennaker RL 2nd, Kilgard MP. Vagus nerve stimulation delivered during motor rehabilitation improves recovery in a rat model of stroke. Neurorehabil Neural Repair. 2014 Sep;28(7):698-706. doi: 10.1177/1545968314521006. Epub 2014 Feb 18.
Results Reference
background
PubMed Identifier
24818637
Citation
Hays SA, Khodaparast N, Ruiz A, Sloan AM, Hulsey DR, Rennaker RL 2nd, Kilgard MP. The timing and amount of vagus nerve stimulation during rehabilitative training affect poststroke recovery of forelimb strength. Neuroreport. 2014 Jun 18;25(9):676-82. doi: 10.1097/WNR.0000000000000154.
Results Reference
background
PubMed Identifier
25147331
Citation
Hays SA, Khodaparast N, Hulsey DR, Ruiz A, Sloan AM, Rennaker RL 2nd, Kilgard MP. Vagus nerve stimulation during rehabilitative training improves functional recovery after intracerebral hemorrhage. Stroke. 2014 Oct;45(10):3097-100. doi: 10.1161/STROKEAHA.114.006654. Epub 2014 Aug 21.
Results Reference
background
PubMed Identifier
27255820
Citation
Hays SA, Ruiz A, Bethea T, Khodaparast N, Carmel JB, Rennaker RL 2nd, Kilgard MP. Vagus nerve stimulation during rehabilitative training enhances recovery of forelimb function after ischemic stroke in aged rats. Neurobiol Aging. 2016 Jul;43:111-8. doi: 10.1016/j.neurobiolaging.2016.03.030. Epub 2016 Apr 7.
Results Reference
background
PubMed Identifier
26542082
Citation
Khodaparast N, Kilgard MP, Casavant R, Ruiz A, Qureshi I, Ganzer PD, Rennaker RL 2nd, Hays SA. Vagus Nerve Stimulation During Rehabilitative Training Improves Forelimb Recovery After Chronic Ischemic Stroke in Rats. Neurorehabil Neural Repair. 2016 Aug;30(7):676-84. doi: 10.1177/1545968315616494. Epub 2015 Nov 4.
Results Reference
background
PubMed Identifier
26058501
Citation
Pruitt DT, Schmid AN, Kim LJ, Abe CM, Trieu JL, Choua C, Hays SA, Kilgard MP, Rennaker RL. Vagus Nerve Stimulation Delivered with Motor Training Enhances Recovery of Function after Traumatic Brain Injury. J Neurotrauma. 2016 May 1;33(9):871-9. doi: 10.1089/neu.2015.3972. Epub 2015 Aug 5.
Results Reference
background
PubMed Identifier
29533186
Citation
Ganzer PD, Darrow MJ, Meyers EC, Solorzano BR, Ruiz AD, Robertson NM, Adcock KS, James JT, Jeong HS, Becker AM, Goldberg MP, Pruitt DT, Hays SA, Kilgard MP, Rennaker RL 2nd. Closed-loop neuromodulation restores network connectivity and motor control after spinal cord injury. Elife. 2018 Mar 13;7:e32058. doi: 10.7554/eLife.32058.
Results Reference
background
PubMed Identifier
29371435
Citation
Meyers EC, Solorzano BR, James J, Ganzer PD, Lai ES, Rennaker RL 2nd, Kilgard MP, Hays SA. Vagus Nerve Stimulation Enhances Stable Plasticity and Generalization of Stroke Recovery. Stroke. 2018 Mar;49(3):710-717. doi: 10.1161/STROKEAHA.117.019202. Epub 2018 Jan 25.
Results Reference
background
PubMed Identifier
21228773
Citation
Engineer ND, Riley JR, Seale JD, Vrana WA, Shetake JA, Sudanagunta SP, Borland MS, Kilgard MP. Reversing pathological neural activity using targeted plasticity. Nature. 2011 Feb 3;470(7332):101-4. doi: 10.1038/nature09656. Epub 2011 Jan 12.
Results Reference
background
PubMed Identifier
30355189
Citation
Kimberley TJ, Pierce D, Prudente CN, Francisco GE, Yozbatiran N, Smith P, Tarver B, Engineer ND, Alexander Dickie D, Kline DK, Wigginton JG, Cramer SC, Dawson J. Vagus Nerve Stimulation Paired With Upper Limb Rehabilitation After Chronic Stroke. Stroke. 2018 Nov;49(11):2789-2792. doi: 10.1161/STROKEAHA.118.022279.
Results Reference
background
PubMed Identifier
26645257
Citation
Dawson J, Pierce D, Dixit A, Kimberley TJ, Robertson M, Tarver B, Hilmi O, McLean J, Forbes K, Kilgard MP, Rennaker RL, Cramer SC, Walters M, Engineer N. Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke. Stroke. 2016 Jan;47(1):143-50. doi: 10.1161/STROKEAHA.115.010477. Epub 2015 Dec 8.
Results Reference
background
PubMed Identifier
29562561
Citation
Kilgard MP, Rennaker RL, Alexander J, Dawson J. Vagus nerve stimulation paired with tactile training improved sensory function in a chronic stroke patient. NeuroRehabilitation. 2018;42(2):159-165. doi: 10.3233/NRE-172273.
Results Reference
background
PubMed Identifier
31875975
Citation
Darrow MJ, Mian TM, Torres M, Haider Z, Danaphongse T, Rennaker RL Jr, Kilgard MP, Hays SA. Restoration of Somatosensory Function by Pairing Vagus Nerve Stimulation with Tactile Rehabilitation. Ann Neurol. 2020 Feb;87(2):194-205. doi: 10.1002/ana.25664. Epub 2020 Jan 7.
Results Reference
background
PubMed Identifier
31857587
Citation
Meyers EC, Kasliwal N, Solorzano BR, Lai E, Bendale G, Berry A, Ganzer PD, Romero-Ortega M, Rennaker RL 2nd, Kilgard MP, Hays SA. Enhancing plasticity in central networks improves motor and sensory recovery after nerve damage. Nat Commun. 2019 Dec 19;10(1):5782. doi: 10.1038/s41467-019-13695-0.
Results Reference
background
PubMed Identifier
31969052
Citation
Darrow MJ, Torres M, Sosa MJ, Danaphongse TT, Haider Z, Rennaker RL, Kilgard MP, Hays SA. Vagus Nerve Stimulation Paired With Rehabilitative Training Enhances Motor Recovery After Bilateral Spinal Cord Injury to Cervical Forelimb Motor Pools. Neurorehabil Neural Repair. 2020 Mar;34(3):200-209. doi: 10.1177/1545968319895480. Epub 2020 Jan 22.
Results Reference
background
PubMed Identifier
12270966
Citation
Heck C, Helmers SL, DeGiorgio CM. Vagus nerve stimulation therapy, epilepsy, and device parameters: scientific basis and recommendations for use. Neurology. 2002 Sep 24;59(6 Suppl 4):S31-7. doi: 10.1212/wnl.59.6_suppl_4.s31.
Results Reference
background
PubMed Identifier
2537589
Citation
Agnew WF, McCreery DB, Yuen TG, Bullara LA. Histologic and physiologic evaluation of electrically stimulated peripheral nerve: considerations for the selection of parameters. Ann Biomed Eng. 1989;17(1):39-60. doi: 10.1007/BF02364272.
Results Reference
background

Learn more about this trial

Wireless Nerve Stimulation Device To Enhance Recovery After Stroke

We'll reach out to this number within 24 hrs